Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN INT 1
Intervet Ireland Limited
QI02A
Pdr+Solv for Soln for Inj
Immunological - Live Vaccine
Bovine
2003-06-06
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Bovilis IBR 2 QUALITATIVE AND QUANTITATIVE COMPOSITION per dose (2 ml) _Active Substance(s):_ IBR virus, strain INT 1 > 5.6 log 10 TCID 50 grown in BEL 26 cells. _Other ingredient(s):_ Traces of neomycin, polymixin, or gentamycin and amphotericin may be present in the product. _Diluent:_ No ingredients knowledge of which is essential for the safe use of the product. For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for solution for injection. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the active immunisation of cattle to reduce both clinical signs of disease and virus excretion after infection with infectious bovine rhinotracheitis. The degree of protection afforded by use of the intramuscular route is slightly less than following intranasal administration. Cattle have been shown to be protected from the worst clinical effects of IBR within 2 days of intranasal and 7 days of intramuscular vaccination with Bovilis IBR. Where an outbreak of IBR occurs, in-contact animals may be vaccinated immediately with Bovilis IBR in an attempt to prevent or reduce the severity of the disease. The vaccine should be used intranasally for this purpose. Annual revaccination is recommended. 4.3 CONTRAINDICATIONS None known 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 22/11/2006_ _CRN 7002474_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Only healthy animals should be vaccinated. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING Read the complete document